Comparative Pharmacology
Head-to-head clinical analysis: KEFUROX IN PLASTIC CONTAINER versus PANIXINE DISPERDOSE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KEFUROX IN PLASTIC CONTAINER versus PANIXINE DISPERDOSE.
KEFUROX IN PLASTIC CONTAINER vs PANIXINE DISPERDOSE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefuroxime is a second-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically PBP-3 and PBP-1a/1b, leading to inhibition of transpeptidase activity and autolysin-mediated cell death.
Panixine is a cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
750 mg to 1.5 g IV every 8 hours; for severe infections, up to 3 g IV every 8 hours.
Cefpodoxime proxetil (Panixine Disperdose) is administered orally (PO) as a dispersible tablet. Typical adult dose: 200 mg PO every 12 hours for 10-14 days for community-acquired pneumonia; 100 mg PO every 12 hours for 5-7 days for acute exacerbation of chronic bronchitis; 200 mg PO single dose for uncomplicated gonorrhea.
None Documented
None Documented
1.2-1.6 hours in adults with normal renal function. Extended to 15-22 hours in end-stage renal disease.
6-8 hours in healthy adults; prolonged in renal impairment (up to 20-30 hours in severe impairment).
Renal: 80-90% unchanged by glomerular filtration and tubular secretion. Biliary: <2% excreted in bile. Fecal: <1%.
Renal excretion of unchanged drug accounts for 70-80% of elimination; biliary/fecal excretion accounts for 10-15%.
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic